Andere talen Circio Holding ASA

Aandelen

TRVX

NO0013033795

Beurs gesloten - Oslo Bors Andere beurzen 16:45:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,7 ^NOK	+0,75%		-6,90%	-62,50%

25/04	Circio Holding ASA rapporteert resultaten voor het gehele jaar eindigend op 31 december 2023	CI
17/04	Circio kondigt in vivo proof-of-concept aan voor zijn circVec circulair RNA-platformtechnologie en versterkte focus op gentherapie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Circio : Annual Report 2023 Report	00:02
Circio Holding ASA: Annual Report 2023	25/04
Circio Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
Circio Holding ASA: Requested Conversion of Convertible Bonds	25/04
Circio Establishes In Vivo Proof-of-Concept for Circular RNA Platform	17/04
Circio to Raise Up to NOK60 Million via Rights Issue	17/04
Circio Terminates Cancer Vaccine License Deal in China	17/04
Circio : Company update 17 April 2024	17/04
Circio announces in vivo proof-of-concept for its circVec circular RNA platform technology and reinforced gene therapy focus	17/04
Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus	17/04
Circio announces intention to raise around NOK 50-60 million in Q2 2024 to extend cash runway to Q2 2025	17/04
Circio terminates TG01 cancer vaccine license option agreement with IOVaxis in China for non-payment	17/04
Circio Holding ASA Terminates TG01 Cancer Vaccine License Option Agreement with IOVaxis therapeutics in China for Non-Payment	17/04
Circio Holding ASA: Requested Conversion of Convertible Bonds	21/03
Circio Partner Exercises Option to License Cancer Vaccine in China	19/03
Circio announces that partner IOVaxis Therapeutics has exercised the option for an exclusive license to mutant RAS cancer vaccine TG01 in China	19/03
Circio Holding ASA Announces Partner IOVaxis Therapeutics Exercises the Option for an Exclusive License to Mutant RAS Cancer Vaccine TG01 in China	19/03
Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds	13/03
Circio Holding ASA: Approval and publication of prospectus	08/03
Circio : The TG01 IND application by Circio’s partner IOVaxis Therapeutics has been approved by the Chinese regulatory authorities	04/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Circio Holding ASA

Aandelen

TRVX

NO0013033795

Andere talen

Filters